Identification

Name
Spirapril
Accession Number
DB01348
Type
Small Molecule
Groups
Approved
Description

Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.

Structure
Thumb
Synonyms
  • Renormax
  • Spirapril
Product Ingredients
IngredientUNIICASInChI Key
Spirapril hydrochlorideOCC25LM89794841-17-5CLDOLNORSLLQDI-OOAIBONUSA-N
International/Other Brands
Renormax
Categories
UNII
96U2K78I3V
CAS number
83647-97-6
Weight
Average: 466.614
Monoisotopic: 466.15961346
Chemical Formula
C22H30N2O5S2
InChI Key
HRWCVUIFMSZDJS-SZMVWBNQSA-N
InChI
InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
IUPAC Name
(8S)-7-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2

Pharmacology

Indication

Spirapril is an ACE inhibitor class drug used to treat hypertension.

Pharmacodynamics

Spirapril is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, spirapril decreases angiotensin II which is a vasoconstrictor and inducer of aldosterone. So by inhibiting the enzymes, aldosterone secreation is decreased (so less sodium is reabsorbed) and there is a decrease in vasoconstriction. Combined, this leades to a decrease in blood pressure.

Mechanism of action

Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Bioavailability is 50% following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Converted to spiraprilat following oral administration.

Route of elimination
Not Available
Half life

30 to 35 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Spirapril Action PathwayDrug action
Spirapril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Spirapril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Spirapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Spirapril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Spirapril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Spirapril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Spirapril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Spirapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Spirapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Spirapril.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Spirapril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Spirapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Spirapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Spirapril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Spirapril.Approved
AloxiprinThe therapeutic efficacy of Spirapril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Spirapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Spirapril.Approved, Withdrawn
AmbrisentanSpirapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Spirapril.Experimental, Investigational
AmifostineSpirapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Spirapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Spirapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Spirapril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Spirapril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Spirapril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Spirapril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Spirapril.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Spirapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Spirapril.Approved, Illicit, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Spirapril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Spirapril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Spirapril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Spirapril.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Spirapril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Spirapril.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Spirapril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Spirapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Spirapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Spirapril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Spirapril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Spirapril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Spirapril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Spirapril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Spirapril.Approved, Investigational
BarnidipineSpirapril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Spirapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Spirapril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Spirapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Spirapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Spirapril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Spirapril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Spirapril.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Spirapril.Approved
BepridilBepridil may increase the hypotensive activities of Spirapril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Spirapril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Spirapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Spirapril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Spirapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Spirapril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Spirapril.Approved
BoceprevirThe serum concentration of Spirapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanBosentan may increase the hypotensive activities of Spirapril.Approved, Investigational
BQ-123Spirapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Spirapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Spirapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Spirapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Spirapril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Spirapril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Spirapril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Spirapril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Spirapril.Approved
BupranololSpirapril may increase the hypotensive activities of Bupranolol.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Spirapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Spirapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Spirapril.Experimental
CafedrineSpirapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Spirapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Spirapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Spirapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Spirapril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Spirapril.Approved
CarbamazepineThe metabolism of Spirapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Spirapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Spirapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Spirapril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Spirapril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Spirapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Spirapril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Spirapril.Approved, Investigational
CeliprololSpirapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Spirapril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Spirapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Spirapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Spirapril.Approved
CicletanineSpirapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Spirapril.Approved
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Spirapril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Spirapril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Spirapril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Spirapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Spirapril.Approved
CloranololSpirapril may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Spirapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Spirapril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Spirapril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Spirapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Spirapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Spirapril.Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Spirapril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Spirapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Spirapril.Approved, Investigational
DelaprilSpirapril may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Spirapril.Approved
DersalazineThe therapeutic efficacy of Spirapril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineSpirapril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Spirapril.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Spirapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Spirapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Spirapril.Approved, Vet Approved
DiethylnorspermineSpirapril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Spirapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Spirapril.Experimental
DiflunisalThe therapeutic efficacy of Spirapril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Spirapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Spirapril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Spirapril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Spirapril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Spirapril.Approved, Withdrawn
DipyridamoleDipyridamole may increase the antihypertensive activities of Spirapril.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Spirapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Spirapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Spirapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Spirapril.Approved, Investigational
DrospirenoneSpirapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Spirapril.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Spirapril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Spirapril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Spirapril.Investigational
EfonidipineSpirapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Spirapril.Approved
EnalaprilEnalapril may increase the hypotensive activities of Spirapril.Approved, Vet Approved
EnalaprilatSpirapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Spirapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Spirapril.Approved, Investigational
EpanololSpirapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Spirapril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Spirapril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Spirapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Spirapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Spirapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Spirapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Spirapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Spirapril.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Spirapril.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Spirapril.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Spirapril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Spirapril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Spirapril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Spirapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Spirapril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Spirapril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Spirapril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Spirapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Spirapril.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Spirapril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Spirapril.Experimental
FelodipineFelodipine may increase the hypotensive activities of Spirapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Spirapril.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Spirapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Spirapril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Spirapril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Spirapril.Experimental
Ferulic acidSpirapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Spirapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Spirapril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Spirapril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Spirapril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Spirapril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Spirapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Spirapril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Spirapril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Spirapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Spirapril.Approved, Vet Approved
GarlicThe serum concentration of Spirapril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Spirapril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Spirapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Spirapril.Approved
GuanazodineSpirapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Spirapril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Spirapril.Approved, Investigational
GuanoclorSpirapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzSpirapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanSpirapril may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Spirapril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Spirapril is combined with Heparin.Approved, Investigational
HexamethoniumSpirapril may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Spirapril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Spirapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Spirapril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Spirapril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Spirapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Spirapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Spirapril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Spirapril.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Spirapril.Approved, Investigational
ImidaprilSpirapril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Spirapril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Spirapril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Spirapril.Approved
IndenololSpirapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Spirapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Spirapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Spirapril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Spirapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Spirapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Spirapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Spirapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Spirapril.Approved, Investigational
IronIron can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Spirapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Spirapril.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Spirapril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Spirapril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Spirapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Spirapril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Spirapril.Approved
LabetalolLabetalol may increase the hypotensive activities of Spirapril.Approved
LacidipineSpirapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Spirapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Spirapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Spirapril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Spirapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Spirapril.Approved
LinsidomineSpirapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Spirapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Spirapril.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Spirapril.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Spirapril.Experimental
LofexidineSpirapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Spirapril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Spirapril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Spirapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Spirapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Spirapril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Spirapril.Approved, Investigational
MacitentanSpirapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Spirapril.Approved
ManidipineSpirapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Spirapril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Spirapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Spirapril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Spirapril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Spirapril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Spirapril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Spirapril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Spirapril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Spirapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Spirapril.Approved, Investigational, Withdrawn
MethoserpidineSpirapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Spirapril.Approved
Methyl salicylateThe therapeutic efficacy of Spirapril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Spirapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Spirapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Spirapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Spirapril.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Spirapril.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Spirapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Spirapril.Approved, Investigational
MetyrosineSpirapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilSpirapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Spirapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Spirapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Spirapril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Spirapril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Spirapril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Spirapril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Spirapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Spirapril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Spirapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Spirapril.Approved, Investigational
MuzolimineSpirapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Spirapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Spirapril.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Spirapril.Approved
NadololNadolol may increase the hypotensive activities of Spirapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Spirapril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Spirapril.Approved
NaftopidilSpirapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Spirapril.Approved, Vet Approved
NebivololSpirapril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Spirapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Spirapril.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Spirapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Spirapril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Spirapril.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Spirapril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Spirapril.Approved
NiguldipineSpirapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineSpirapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Spirapril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Spirapril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Spirapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Spirapril.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Spirapril can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Spirapril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Spirapril.Approved
ObinutuzumabSpirapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Spirapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spirapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Spirapril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Spirapril.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Spirapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Spirapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Spirapril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Spirapril.Approved
OxprenololSpirapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Spirapril.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Spirapril.Experimental, Nutraceutical
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Spirapril.Approved
PargylinePargyline may increase the hypotensive activities of Spirapril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Spirapril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Spirapril can be decreased when used in combination with Patent Blue.Approved
PenbutololSpirapril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Spirapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Spirapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Spirapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Spirapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Spirapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Spirapril.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Spirapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Spirapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Spirapril.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Spirapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Spirapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Spirapril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Spirapril.Approved
PindololPindolol may increase the hypotensive activities of Spirapril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Spirapril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Spirapril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Spirapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Spirapril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Spirapril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Spirapril.Withdrawn
Platelet Activating FactorSpirapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Spirapril.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Spirapril.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Spirapril.Approved, Investigational
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Spirapril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Spirapril.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Spirapril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Spirapril.Approved
PregabalinThe risk or severity of angioedema can be increased when Spirapril is combined with Pregabalin.Approved, Illicit, Investigational
ProcaineProcaine may increase the hypotensive activities of Spirapril.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Spirapril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Spirapril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Spirapril.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Spirapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Spirapril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Spirapril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Spirapril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Spirapril.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Spirapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Spirapril.Approved
QuinineQuinine may increase the hypotensive activities of Spirapril.Approved
RamiprilRamipril may increase the hypotensive activities of Spirapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Spirapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Spirapril.Approved
RescinnamineSpirapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Spirapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Spirapril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Spirapril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Spirapril.Approved
RituximabSpirapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Spirapril.Approved, Investigational, Withdrawn
SacubitrilThe risk or severity of angioedema can be increased when Spirapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Spirapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Spirapril.Approved
Salicylic acidThe therapeutic efficacy of Spirapril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Spirapril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Spirapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Spirapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Spirapril.Approved
SelegilineSelegiline may increase the hypotensive activities of Spirapril.Approved, Investigational, Vet Approved
SelexipagSpirapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Spirapril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Spirapril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Spirapril.Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Spirapril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Spirapril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Spirapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Spirapril.Approved, Investigational
SitaxentanSpirapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Spirapril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicSpirapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Spirapril.Investigational
St. John's WortThe metabolism of Spirapril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Spirapril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Spirapril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Spirapril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Spirapril.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Spirapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Spirapril.Approved, Investigational
TalinololSpirapril may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Spirapril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Spirapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Spirapril.Approved, Investigational
TemocaprilSpirapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Spirapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Spirapril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Spirapril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Spirapril.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Spirapril.Approved
TerlipressinSpirapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineSpirapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineSpirapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Spirapril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Spirapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Spirapril.Approved
TiboloneSpirapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenSpirapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Spirapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Spirapril.Investigational
TipranavirThe serum concentration of Spirapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Spirapril.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Spirapril.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Spirapril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Spirapril.Approved
TolonidineSpirapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Spirapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Spirapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Spirapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Spirapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Spirapril.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Spirapril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Spirapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Spirapril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Spirapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Spirapril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Spirapril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Spirapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Spirapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Spirapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Spirapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Spirapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Spirapril.Investigational
Trolamine salicylateThe therapeutic efficacy of Spirapril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Spirapril.Approved, Investigational
UnoprostoneSpirapril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Spirapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Spirapril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Spirapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Spirapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Spirapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Spirapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Spirapril.Approved, Investigational
VincamineSpirapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineSpirapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideSpirapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineSpirapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Spirapril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Spirapril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Spirapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Spirapril.Approved, Investigational, Withdrawn
ZofenoprilSpirapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Spirapril.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or iron supplements within 2 hours of taking this medication.
  • Herbs that may attenuate the antihypertensive effect of spirapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of spirapril.
  • Spirapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

References

General References
  1. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161]
  2. Noble S, Sorkin EM: Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. [PubMed:7601014]
  3. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157]
  4. Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G: Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. Scand J Urol Nephrol. 1999 Feb;33(1):57-62. [PubMed:10100366]
External Links
Human Metabolome Database
HMDB0015438
PubChem Compound
5311447
PubChem Substance
46506126
ChemSpider
4470933
BindingDB
50017124
ChEBI
135756
ChEMBL
CHEMBL431
Therapeutic Targets Database
DAP000911
PharmGKB
PA164776913
Wikipedia
Spirapril
ATC Codes
C09AA11 — Spirapril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0293 mg/mLALOGPS
logP1.79ALOGPS
logP1.6ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.62ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity121.94 m3·mol-1ChemAxon
Polarizability48.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5287
Blood Brain Barrier-0.9614
Caco-2 permeable-0.83
P-glycoprotein substrateSubstrate0.8223
P-glycoprotein inhibitor INon-inhibitor0.6938
P-glycoprotein inhibitor IINon-inhibitor0.7426
Renal organic cation transporterNon-inhibitor0.8836
CYP450 2C9 substrateNon-substrate0.833
CYP450 2D6 substrateNon-substrate0.8553
CYP450 3A4 substrateNon-substrate0.5658
CYP450 1A2 substrateNon-inhibitor0.8439
CYP450 2C9 inhibitorNon-inhibitor0.7259
CYP450 2D6 inhibitorNon-inhibitor0.8813
CYP450 2C19 inhibitorNon-inhibitor0.5956
CYP450 3A4 inhibitorInhibitor0.5073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6331
Ames testNon AMES toxic0.8764
CarcinogenicityNon-carcinogens0.908
BiodegradationNot ready biodegradable0.9115
Rat acute toxicity2.2396 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.5579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
N-acyl-L-alpha-amino acids / Alpha amino acid esters / Alpha amino acid amides / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Fatty acid esters / Dithioketals / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives
show 12 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
  2. Maul B, Krause W, Pankow K, Becker M, Gembardt F, Alenina N, Walther T, Bader M, Siems WE: Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81. [PubMed:16126915]
  3. Hermida RC, Ayala DE, Fontao MJ, Mojon A, Alonso I, Fernandez JR: Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int. 2010 May;27(3):560-74. doi: 10.3109/07420528.2010.485411. [PubMed:20524801]
  4. Arend U, Albrecht S, Meisel E, Schmidt J: [Influence of ACE inhibitor spirapril on left ventricular hypertrophy]. Fortschr Med Orig. 2002 Dec 5;120(4):147-50. [PubMed:12613273]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 30, 2007 12:15 / Updated on July 02, 2018 20:46